Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the USFDA to manufacture and market Diroximel Fumarate Delayed-Release Capsules in 231 mg strength. Diroximel Fumarate is used in the treatment of relapsing forms of multiple sclerosis and is the generic equivalent of Biogen's Vumerity. With final approval secured, Zydus can now commercially launch the product in the US market through its established generics business. The approval adds to Zydus's growing portfolio of USFDA-approved complex generics and specialty products. This strengthens the company's presence in the US neurology and central nervous system (CNS) therapeutic segment.
Positive for shareholders — the approval opens a new revenue stream in the lucrative US generics market and reinforces Zydus's USFDA compliance track record. Expect a short-term positive sentiment on the stock, with actual earnings impact depending on market share capture and existing competition.